JP6659535B2 - アミノ酸及びペプチド接合体及び接合方法 - Google Patents

アミノ酸及びペプチド接合体及び接合方法 Download PDF

Info

Publication number
JP6659535B2
JP6659535B2 JP2016522936A JP2016522936A JP6659535B2 JP 6659535 B2 JP6659535 B2 JP 6659535B2 JP 2016522936 A JP2016522936 A JP 2016522936A JP 2016522936 A JP2016522936 A JP 2016522936A JP 6659535 B2 JP6659535 B2 JP 6659535B2
Authority
JP
Japan
Prior art keywords
peptide
amino acid
xaa
alkyl
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016522936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523891A (ja
JP2016523891A5 (enExample
Inventor
アン ブリンブル マーガレット
アン ブリンブル マーガレット
ヒュー ライト トーマス
ヒュー ライト トーマス
ロードリック ダンバー ピーター
ロードリック ダンバー ピーター
マーティン ウィリアムズ ジェフリー
マーティン ウィリアムズ ジェフリー
Original Assignee
オークランド ユニサービシーズ リミティド
オークランド ユニサービシーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オークランド ユニサービシーズ リミティド, オークランド ユニサービシーズ リミティド filed Critical オークランド ユニサービシーズ リミティド
Publication of JP2016523891A publication Critical patent/JP2016523891A/ja
Publication of JP2016523891A5 publication Critical patent/JP2016523891A5/ja
Application granted granted Critical
Publication of JP6659535B2 publication Critical patent/JP6659535B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2016522936A 2013-06-28 2014-06-27 アミノ酸及びペプチド接合体及び接合方法 Expired - Fee Related JP6659535B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ61265413 2013-06-28
NZ612654 2013-06-28
PCT/IB2014/062648 WO2014207708A2 (en) 2013-06-28 2014-06-27 Amino acid and peptide conjugates and conjugation process

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019194647A Division JP2020023567A (ja) 2013-06-28 2019-10-25 アミノ酸及びペプチド接合体及び接合方法

Publications (3)

Publication Number Publication Date
JP2016523891A JP2016523891A (ja) 2016-08-12
JP2016523891A5 JP2016523891A5 (enExample) 2017-08-03
JP6659535B2 true JP6659535B2 (ja) 2020-03-04

Family

ID=52142779

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016522936A Expired - Fee Related JP6659535B2 (ja) 2013-06-28 2014-06-27 アミノ酸及びペプチド接合体及び接合方法
JP2019194647A Pending JP2020023567A (ja) 2013-06-28 2019-10-25 アミノ酸及びペプチド接合体及び接合方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019194647A Pending JP2020023567A (ja) 2013-06-28 2019-10-25 アミノ酸及びペプチド接合体及び接合方法

Country Status (8)

Country Link
US (2) US10576144B2 (enExample)
EP (2) EP3013789B1 (enExample)
JP (2) JP6659535B2 (enExample)
CN (2) CN109893648A (enExample)
AU (3) AU2014300503B2 (enExample)
CA (1) CA2953747A1 (enExample)
TW (2) TW201920229A (enExample)
WO (1) WO2014207708A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3013789B1 (en) 2013-06-28 2020-03-04 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
RU2017126206A (ru) * 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
WO2019043604A1 (en) * 2017-08-30 2019-03-07 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHOD, AND USES THEREOF
JP2021501784A (ja) * 2017-11-06 2021-01-21 オークランド ユニサービシーズ リミティド ペプチド複合体ｃｇｒｐ受容体アンタゴニストおよびその調製方法および使用方法
CA3085377A1 (en) 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Optimised compounds
MX2020009950A (es) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
KR20210149050A (ko) * 2019-03-04 2021-12-08 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
AU2020302839B2 (en) 2019-06-26 2025-08-14 Ena Respiratory Pty Ltd Novel molecules
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
CN111921001A (zh) * 2020-08-19 2020-11-13 兰州百源基因技术有限公司 一种用于伤口愈合的薄膜及其制备方法
US12281149B2 (en) 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
EP4488283A1 (en) * 2022-04-08 2025-01-08 Chugai Seiyaku Kabushiki Kaisha Production method for peptide compound

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
DE3813821A1 (de) 1988-04-22 1989-11-02 Hoechst Ag Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH02172946A (ja) 1988-12-26 1990-07-04 Shinetsu Sakusan Vinyl Kk カルボン酸アルケニルエステルの製造方法
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
EP0686260B1 (en) 1993-02-05 2003-07-09 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
US6310180B1 (en) 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
DE4331011A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
JPH08248579A (ja) 1995-03-14 1996-09-27 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料及びその処理方法
US5994294A (en) 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
AUPO007396A0 (en) 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
DE69837273T2 (de) * 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DK1147117T3 (da) 1999-02-01 2004-10-25 Eisai Co Ltd Immunologiske adjuvansforbindelser
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
EP1252309A2 (en) 2000-01-28 2002-10-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
AU2001273639A1 (en) 2000-06-26 2002-01-08 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6506875B1 (en) 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
GB0030067D0 (en) 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
IL162319A0 (en) 2001-12-04 2005-11-20 Univ Ben Gurion Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
FR2836684B1 (fr) * 2002-03-04 2004-12-17 Inst Nat Sante Rech Med Peptides ras mutes et leur utilisation en immunotherapie
EP2070949B1 (en) * 2002-06-10 2013-01-16 Vaccinex, Inc. C35 antibodies and their use in the treatment of cancer
GB0214528D0 (en) 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
EP1523331B1 (en) 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
JP4619121B2 (ja) * 2002-08-12 2011-01-26 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Ｔヘルパーエピトープおよび細胞傷害性ｔリンパ球（ｃｔｌ）エピトープを含む新規な免疫原性リポペプチド
ES2369664T3 (es) 2002-08-12 2011-12-02 The Council Of The Queensland Institute Of Medical Research Lipopéptidos inmunogénicos novedosos que comprenden epítopos de células t cooperadoras y de células b.
US20070048329A1 (en) 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
WO2005000870A2 (en) * 2003-05-30 2005-01-06 Ludwig Institute Of Cancer Research Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
EP1664001A2 (en) 2003-07-29 2006-06-07 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
EP2497831B1 (en) 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
EP1850832B1 (en) 2005-02-07 2014-12-31 Lipotek PTY Ltd Adjuvanting material
MX2007009598A (es) 2005-02-08 2008-03-10 Queensland Inst Med Res Moleculas inmunogenicas.
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
EP1888121A2 (en) 2005-05-12 2008-02-20 Tapestry Pharmaceuticals, Inc. Anticancer targeted conjugates comprising a succinyl or glutaryl linker
EP1943344A2 (en) * 2005-10-04 2008-07-16 The Ludwig Institute for Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
CA2620899A1 (en) 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles useful in the treatment of inflammation
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
EP1963358A4 (en) 2005-12-06 2009-03-25 Univ Australian TREATMENT OF DISEASES ASSOCIATED WITH THE EPSTEIN-BARR-VIRUS
WO2007078879A2 (en) 2005-12-21 2007-07-12 Vaxinnate Corporation Lipopeptide compositions and methods of use thereof
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US20090123488A1 (en) 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
EA016818B1 (ru) 2007-01-15 2012-07-30 Глаксосмитклайн Байолоджикалс С.А. Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP3533461A3 (en) 2007-03-26 2019-12-18 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
WO2008151197A2 (en) 2007-06-04 2008-12-11 The Regents Of The University Of California Tumor-derived endogenous toll-like receptor 4 ligands
US20100266623A1 (en) 2008-07-07 2010-10-21 The University Of Melbourne Synthetic, self adjuvanting vaccines
US20110262473A1 (en) 2008-07-07 2011-10-27 The University Of Melbourne Synthetic vaccine component
EP2334332A4 (en) 2008-09-05 2013-01-09 Id Biomedical Corp Quebec NEW COMPOSITIONS AND NEW ADJUVANTS
WO2010030722A1 (en) 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
US20130029358A1 (en) 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
WO2011156686A2 (en) 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
US20140227305A1 (en) 2010-08-25 2014-08-14 Romana Lange-Ruiss Epstein-barr-virus vaccine
AU2011295845B2 (en) 2010-09-01 2016-09-22 Baylor College Of Medicine EBV-specific cytotoxic T-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (NPC)
AR082980A1 (es) 2010-09-14 2013-01-23 Council Scient Ind Res Inmunogeno sintetico util para generar inmunidad y proteccion contra patogenos a largo plazo
BR112013006718B1 (pt) 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
WO2012069188A1 (en) 2010-11-24 2012-05-31 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V Continuous flow processes for photoconjugation of high-molecular chemical entities
US9187534B2 (en) * 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
SG194727A1 (en) 2011-05-13 2013-12-30 Univ Nanyang Tech Method for modification of organic molecules
US20120328660A1 (en) 2011-06-03 2012-12-27 Tsuji Takemasa Immunogenic compositions useful in provoking an integrated response to tumor antigens
CN102839186A (zh) * 2011-06-21 2012-12-26 上海生物制品研究所有限责任公司 表达ny-eso-1重组耻垢分枝杆菌的制备及应用
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
WO2013036543A2 (en) * 2011-09-10 2013-03-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
WO2013181597A2 (en) 2012-05-31 2013-12-05 Synchem, Inc. Thiol-ene click chemistry for drug conjugates
US9861702B2 (en) 2012-10-22 2018-01-09 Wisconsin Alumni Research Foundation Lipid-conjugated rhamnose for immune system recruitment and oncotherapy
CA2893918C (en) 2012-12-06 2020-11-24 Callaghan Innovation Research Limited Conjugate compounds
EP3013789B1 (en) 2013-06-28 2020-03-04 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
RU2017126206A (ru) 2014-12-23 2019-01-25 Маргарет Анне БРИМБЛЕ Аминокислотные и пептидные конъюгаты и направления их использования
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process

Also Published As

Publication number Publication date
CN105555756A (zh) 2016-05-04
WO2014207708A3 (en) 2015-04-16
TW201542583A (zh) 2015-11-16
JP2016523891A (ja) 2016-08-12
EP3013789A4 (en) 2017-02-08
US10576144B2 (en) 2020-03-03
HK1224279A1 (en) 2017-08-18
EP3013789A2 (en) 2016-05-04
TW201920229A (zh) 2019-06-01
AU2019200884B2 (en) 2020-11-05
US20200306370A1 (en) 2020-10-01
EP3013789B1 (en) 2020-03-04
CA2953747A1 (en) 2014-12-31
AU2014300503B2 (en) 2018-11-22
AU2019200884A1 (en) 2019-03-21
US20170095554A1 (en) 2017-04-06
WO2014207708A2 (en) 2014-12-31
CN105555756B (zh) 2018-12-07
JP2020023567A (ja) 2020-02-13
TWI655201B (zh) 2019-04-01
AU2020277160A1 (en) 2020-12-24
AU2014300503A1 (en) 2016-01-21
EP3604271A1 (en) 2020-02-05
CN109893648A (zh) 2019-06-18

Similar Documents

Publication Publication Date Title
JP6659535B2 (ja) アミノ酸及びペプチド接合体及び接合方法
US11014960B2 (en) Amino acid and peptide conjugates and uses thereof
JP7161404B2 (ja) アミノ酸及びペプチド接合体及び接合方法
JP2020532534A (ja) ペプチド接合体、接合プロセス及びそれらの使用
HK40013754A (en) Peptides for amino acid and peptide conjugates and conjugation process
HK1224279B (en) Amino acid and peptide conjugates and conjugation process

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181010

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200206

R150 Certificate of patent or registration of utility model

Ref document number: 6659535

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees